Renal denervation is a catheter-based minimally-invasive procedure. It is a therapy performed by radiofrequency or ultrasound ablation for uncontrolled hypertension. Renal denervation is performed through endovascular catheter-based procedure to treat hypertension, which is beyond medication control. The procedure consists of a catheter that emits radiofrequency energy across multiple electrodes. Radiofrequency pulse is applied to the renal artery, which causes the wall of artery to ablate, reducing the nerve activity, thereby reducing blood pressure. The progress of catheter-based interventional therapies has yielded impressive results in certifying enhanced blood pressure control in patients with complaints of uncontrolled hypertension, vascular, and cardiovascular diseases.

Get Exclusive Sample Report at:

Market Dynamics

Increasing prevalence of hypertension is a major factor driving renal denervation device market growth. According to the World Health Organization (WHO), the prevalence of high blood pressure in adults aged 25 and above was around 40% in 2008 and number of people with uncontrolled hypertension increased from 600 million in 1980 to around 1 billion in 2008. According to Fourth National Family Health Survey hypertension led to 1.63 million deaths in India in 2016 as compared to 0.78 million in 1990 and hypertension increased from 21 million in 1990 to 39 million in 2016.

Increasing prevalence of hypertension is expected to propel growth of the renal denervation devices market

Increasing prevalence of cardiovascular diseases (CVDs) and hypertension is expected to drive demand for renal denervation devices worldwide. For instance, according to the World Health Organization (WHO), the prevalence of hypertension in adults aged 25 and above was around 40% in 2008 worldwide. According to the American College of Cardiology (ACC)/the American Heart Association (AHA), the clinical practice guidelines of hypertension have modified the definition of hypertension, which has increased the prevalence of hypertension to 45.6% or around 103.3 million people in U.S. in 2017.

Increasing research and development activities and regulatory approvals in Europe is expected to bolster the market growth

Europe holds dominant position in the global renal denervation device market, owing to increasing research and development activities and regulatory approvals. For instance, in February 2014, Cordis Corporation, a division of Johnson & Johnson, received CE Mark for Renlane renal denervation system. The system consists of a unique, helical shaped, irrigated, multi-electrode ablation catheter with a multi-channel radiofrequency (RF) ablation system.

Moreover, increasing number of clinical trials on renal denervation devices is also expected to boost the market growth. For instance, multi-center, international, single-blind, randomized, sham-controlled clinical trials of RADIANCE-HTN SOLO were conducted at 21 centers in the U.S. and 18 in Europe. The trials meet primary efficacy endpoint, according to an announcement by ReCor Medical in May 2018.

Buy Now This Report:

Key Players

Major players operating in the global renal denervation device market include, St. Jude Medical, Inc., ReCor Medical Inc., Boston Scientific Corporation, Cardiosonic Ltd, Medtronic Plc., Kona Medical, Inc., Mercator Medsystems, Inc., Terumo Corporation, Abbott Laboratories, and Theragenics Corporation.